PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28880247-6	2017	After Lat B or Jas treatment, the Ret-F-actin association induced by GDNF was impaired or enhanced respectively and then the levels of Ret translocated into lipid rafts were correspondingly inhibited or promoted.	jasplakinolide	15-18	ret proto-oncogene	Mus musculus	34-37
28880247-6	2017	After Lat B or Jas treatment, the Ret-F-actin association induced by GDNF was impaired or enhanced respectively and then the levels of Ret translocated into lipid rafts were correspondingly inhibited or promoted.	jasplakinolide	15-18	glial cell line derived neurotrophic factor	Mus musculus	69-73
28880247-6	2017	After Lat B or Jas treatment, the Ret-F-actin association induced by GDNF was impaired or enhanced respectively and then the levels of Ret translocated into lipid rafts were correspondingly inhibited or promoted.	jasplakinolide	15-18	ret proto-oncogene	Mus musculus	135-138
28378936-7	2017	However, Tpm2.1 overexpression consistently enhanced sensitivity to anoikis as well as apoptosis induced by the actin targeting drug jasplakinolide (JASP).	jasplakinolide	133-147	tropomyosin 2	Rattus norvegicus	9-13
28457943-6	2017	SMG also inhibited BMP2-Smad signaling, which was rescued by actin cytoskeleton stabilizing agent, Jasplakinolide (JAS).	jasplakinolide	99-113	bone morphogenetic protein 2	Homo sapiens	19-23
28457943-6	2017	SMG also inhibited BMP2-Smad signaling, which was rescued by actin cytoskeleton stabilizing agent, Jasplakinolide (JAS).	jasplakinolide	115-118	bone morphogenetic protein 2	Homo sapiens	19-23
28797107-0	2017	Jasplakinolide induces primary cilium formation through cell rounding and YAP inactivation.	jasplakinolide	0-14	Yes1 associated transcriptional regulator	Homo sapiens	74-77
28378936-7	2017	However, Tpm2.1 overexpression consistently enhanced sensitivity to anoikis as well as apoptosis induced by the actin targeting drug jasplakinolide (JASP).	jasplakinolide	149-153	tropomyosin 2	Rattus norvegicus	9-13
27306926-9	2016	These events were all rescued by an actin stabilisation agent, jasplakinolide as well as geranylgeraniol, indicating that damages of the actin integrity from disrupted activation of RhoA/Rac-1 lies at the center of simvastatin-induced contractile dysfunction and apoptosis in vascular smooth muscle.	jasplakinolide	63-77	ras homolog family member A	Rattus norvegicus	182-186
28904289-3	2017	The restoration of YAP activation rescues the cells from apoptosis: both the retrovirus-mediated expression of constitutively active YAP and the stabilization of the actomyosin cytoskeleton by jasplakinolide prevent cell death.	jasplakinolide	193-207	yes-associated protein 1	Mus musculus	19-22
27306926-9	2016	These events were all rescued by an actin stabilisation agent, jasplakinolide as well as geranylgeraniol, indicating that damages of the actin integrity from disrupted activation of RhoA/Rac-1 lies at the center of simvastatin-induced contractile dysfunction and apoptosis in vascular smooth muscle.	jasplakinolide	63-77	Rac family small GTPase 1	Rattus norvegicus	187-192
26001192-6	2015	Jasplakinolide increased the F-actin content of TREK-1 deficient cells, similar to the effect of TREK-1 overexpression in control cells.	jasplakinolide	0-14	potassium two pore domain channel subfamily K member 2	Homo sapiens	48-54
26555617-4	2015	For example, the F-actin stabilizing molecules, phalloidin and jasplakinolide, bind to actin structures in yeast and human cells, whereas phalloidin does not bind actin structures of Aspergillus.	jasplakinolide	63-77	actin	Saccharomyces cerevisiae S288C	19-24
26555617-4	2015	For example, the F-actin stabilizing molecules, phalloidin and jasplakinolide, bind to actin structures in yeast and human cells, whereas phalloidin does not bind actin structures of Aspergillus.	jasplakinolide	63-77	actin	Saccharomyces cerevisiae S288C	87-92
26555617-4	2015	For example, the F-actin stabilizing molecules, phalloidin and jasplakinolide, bind to actin structures in yeast and human cells, whereas phalloidin does not bind actin structures of Aspergillus.	jasplakinolide	63-77	actin	Saccharomyces cerevisiae S288C	87-92
26555617-9	2015	In contrast to wild type A. fumigatus, F-actin in this strain binds phalloidin, and pharmacological stabilization of these actin structures with jasplakinolide inhibits germination and alters morphogenesis in a dose-dependent manner.	jasplakinolide	145-159	actin	Saccharomyces cerevisiae S288C	123-128
26555617-11	2015	Our findings show that minor differences in actin protein sequence account for loss of phalloidin and jasplakinolide sensitivity in Aspergillus species.	jasplakinolide	102-116	actin	Saccharomyces cerevisiae S288C	44-49
26001192-14	2015	CONCLUSION: Although cytochalasin D, jasplakinolide and nocodazole altered the F-actin and alpha-tubulin structures of control and TREK-1 deficient AEC, the changes in cytokine secretion from TREK-1 deficient cells cannot be explained by cytoskeletal rearrangements in these cells.	jasplakinolide	37-51	potassium two pore domain channel subfamily K member 2	Homo sapiens	131-137
27358052-9	2016	Inhibition of HCO3 (-) absorption by HMGB1 was eliminated by bath amiloride, 0 Na(+) bath, and the F-actin stabilizer jasplakinolide, three conditions that selectively prevent inhibition of MTAL HCO3 (-) absorption mediated through NHE1.	jasplakinolide	118-132	high mobility group box 1	Rattus norvegicus	37-42
27194588-7	2016	Consistent with this function, the LTP deficit of Cpne6 knockout mice is rescued by the actin stabilizer jasplakinolide.	jasplakinolide	105-119	copine VI	Mus musculus	50-55
26555261-11	2016	Jasplakinolide-induced actin polymerization synergizes with TGFbeta to facilitate MRTF-dependent Nox4 mRNA expression/promoter activation.	jasplakinolide	0-14	NADPH oxidase 4	Homo sapiens	97-101
27825172-7	2016	Pre-exposure to either the actin-depolymerizing agent cytochalasin D or the actin-polymerizing agent jasplakinolide inhibited CyPA secretion induced by ox-LDL.	jasplakinolide	101-115	peptidylprolyl isomerase A	Rattus norvegicus	126-130
26096143-7	2015	Reduction of actin dynamics with jasplakinolide suppressed the germination and tube growth phenotypes in act11 pollen, suggesting that the underlying mechanisms involve an increase in actin dynamics.	jasplakinolide	33-47	actin-12	Arabidopsis thaliana	13-18
26096143-7	2015	Reduction of actin dynamics with jasplakinolide suppressed the germination and tube growth phenotypes in act11 pollen, suggesting that the underlying mechanisms involve an increase in actin dynamics.	jasplakinolide	33-47	actin-11	Arabidopsis thaliana	105-110
26096143-7	2015	Reduction of actin dynamics with jasplakinolide suppressed the germination and tube growth phenotypes in act11 pollen, suggesting that the underlying mechanisms involve an increase in actin dynamics.	jasplakinolide	33-47	actin-12	Arabidopsis thaliana	184-189
26001192-12	2015	IL-6 and MCP-1 secretions from control and TREK-1 deficient cells after TNF-alpha+jasplakinolide or TNF-alpha+nocodazole treatment was similar to the effect of TNF-alpha alone.	jasplakinolide	82-96	potassium two pore domain channel subfamily K member 2	Homo sapiens	43-49
25788662-5	2015	We found that treatment of CHX-arrested oocytes with the actin filament-stabilizing agent Jasplakinolide (Jasp) delayed GVBD following release from CHX arrest and that this was correlated with reduced maturation-promoting factor (MPF) activity.	jasplakinolide	90-104	mesothelin	Mus musculus	201-228
25788662-5	2015	We found that treatment of CHX-arrested oocytes with the actin filament-stabilizing agent Jasplakinolide (Jasp) delayed GVBD following release from CHX arrest and that this was correlated with reduced maturation-promoting factor (MPF) activity.	jasplakinolide	90-104	mesothelin	Mus musculus	230-233
25788662-5	2015	We found that treatment of CHX-arrested oocytes with the actin filament-stabilizing agent Jasplakinolide (Jasp) delayed GVBD following release from CHX arrest and that this was correlated with reduced maturation-promoting factor (MPF) activity.	jasplakinolide	90-94	mesothelin	Mus musculus	201-228
25788662-5	2015	We found that treatment of CHX-arrested oocytes with the actin filament-stabilizing agent Jasplakinolide (Jasp) delayed GVBD following release from CHX arrest and that this was correlated with reduced maturation-promoting factor (MPF) activity.	jasplakinolide	90-94	mesothelin	Mus musculus	230-233
24626324-10	2014	In parallel, polymerization of actin microfilaments induced by Jas upregulated the expression of alpha-SMA and collagen 1, and also enhanced the migration and adhesion properties of HSC-T6 cells.	jasplakinolide	63-66	actin gamma 2, smooth muscle	Rattus norvegicus	97-106
25774599-4	2015	Like PP1, G-actin associated with the functional core of PPP1R15 family members and G-actin depletion, by the marine toxin jasplakinolide, destabilised the endogenous PPP1R15A-PP1 complex.	jasplakinolide	123-137	protein phosphatase 1 regulatory subunit 15A	Homo sapiens	167-175
24223978-6	2013	Actin stabilization with jasplakinolide reduced AJ redistribution, and live imaging of myosin II along elongating contacts revealed fragmented, expanding and contracting actomyosin networks, suggesting a mechanism for lateral AJ mobility.	jasplakinolide	25-39	Actin 79B	Drosophila melanogaster	0-5
24238996-6	2014	Moreover, we demonstrated that Smurf1 localized in HB-like F-actin aggregates in a cell culture system via treatment with the actin-stabilizing toxin jasplakinolide (jpk).	jasplakinolide	150-164	SMAD specific E3 ubiquitin protein ligase 1	Homo sapiens	31-37
23595955-7	2013	The role for actin polymerization in integrin affinity regulation was examined using the actin modulating agent jasplakinolide, which decreased beta1 -integrin affinity.	jasplakinolide	112-126	hemoglobin, beta adult major chain	Mus musculus	144-149
23261645-5	2013	Jaspamide (10 muM) inhibited Kv1.5 activity by 98.5%.	jasplakinolide	0-9	latexin	Homo sapiens	14-17
23261645-5	2013	Jaspamide (10 muM) inhibited Kv1.5 activity by 98.5%.	jasplakinolide	0-9	potassium voltage-gated channel subfamily A member 5	Homo sapiens	29-34
23261645-6	2013	Jaspamide also inhibited other channels including Cav1.2, Cav3.2, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected.	jasplakinolide	0-9	calcium voltage-gated channel subunit alpha1 C	Homo sapiens	50-56
23261645-6	2013	Jaspamide also inhibited other channels including Cav1.2, Cav3.2, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected.	jasplakinolide	0-9	calcium voltage-gated channel subunit alpha1 H	Homo sapiens	58-64
23261645-6	2013	Jaspamide also inhibited other channels including Cav1.2, Cav3.2, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected.	jasplakinolide	0-9	hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2	Homo sapiens	70-74
23261645-8	2013	Jaspamide (30 nM to 30 muM) decreased cardiomyocyte cell indices and beat amplitude, putative measurements of cell viability and cardiac contractility, respectively.	jasplakinolide	0-9	latexin	Homo sapiens	23-26
23147069-4	2013	The method capabilities are demonstrated with monocytic cell lines (THP-1) treated by Jasplakinolide (a stabilizer of polymerized actin), LatrunculinA (an inhibitor of actin polymerization), and with the plasma of patients suffering from ARDS.	jasplakinolide	86-100	GLI family zinc finger 2	Homo sapiens	68-73
22956334-5	2012	Moreover, the inhibition of actin polymerization blocked the FSS-induced activation of Ccn2, whereas inducing F-actin formation using cytochalasin D and jasplakinolide enhanced Ccn2 expression in the same cells.	jasplakinolide	153-167	cellular communication network factor 2	Mus musculus	177-181
23226422-7	2012	Actin stabilization by jasplakinolide enhanced the late EPC apoptosis induced by VEGF deprivation, and significantly impaired late EPC proliferation, adhesion, migration and tube formation.	jasplakinolide	23-37	vascular endothelial growth factor A	Homo sapiens	81-85
22918941-3	2012	We found that latrunculin A (LatA) and jasplakinolide, actin drugs that release mDia1 from actin filament barbed ends, stimulated stable MT formation in serum-starved fibroblasts and caused a redistribution of mDia1 onto MTs.	jasplakinolide	39-53	diaphanous related formin 1	Mus musculus	80-85
22918941-3	2012	We found that latrunculin A (LatA) and jasplakinolide, actin drugs that release mDia1 from actin filament barbed ends, stimulated stable MT formation in serum-starved fibroblasts and caused a redistribution of mDia1 onto MTs.	jasplakinolide	39-53	diaphanous related formin 1	Mus musculus	210-215
22592318-6	2012	Indeed, whereas Jasplakinolide, an actin cytoskeleton-stabilizing agent, mimicked p57(KIP2)"s pro-apoptotic effect, destabilizing the actin cytoskeleton with cytochalsin D reversed p57(KIP2)"s pro-apoptotic function.	jasplakinolide	16-30	cyclin dependent kinase inhibitor 1C	Homo sapiens	82-85
22592318-6	2012	Indeed, whereas Jasplakinolide, an actin cytoskeleton-stabilizing agent, mimicked p57(KIP2)"s pro-apoptotic effect, destabilizing the actin cytoskeleton with cytochalsin D reversed p57(KIP2)"s pro-apoptotic function.	jasplakinolide	16-30	cyclin dependent kinase inhibitor 1C	Homo sapiens	86-90
22592318-6	2012	Indeed, whereas Jasplakinolide, an actin cytoskeleton-stabilizing agent, mimicked p57(KIP2)"s pro-apoptotic effect, destabilizing the actin cytoskeleton with cytochalsin D reversed p57(KIP2)"s pro-apoptotic function.	jasplakinolide	16-30	cyclin dependent kinase inhibitor 1C	Homo sapiens	181-184
22592318-6	2012	Indeed, whereas Jasplakinolide, an actin cytoskeleton-stabilizing agent, mimicked p57(KIP2)"s pro-apoptotic effect, destabilizing the actin cytoskeleton with cytochalsin D reversed p57(KIP2)"s pro-apoptotic function.	jasplakinolide	16-30	cyclin dependent kinase inhibitor 1C	Homo sapiens	185-189
22357954-7	2012	By contrast, stabilization of filamentous actin with jasplakinolide markedly augmented actin vertex enrichment.	jasplakinolide	53-67	actin	Saccharomyces cerevisiae S288C	42-47
22357954-7	2012	By contrast, stabilization of filamentous actin with jasplakinolide markedly augmented actin vertex enrichment.	jasplakinolide	53-67	actin	Saccharomyces cerevisiae S288C	87-92
22271892-7	2012	In in vitro differentiation assays, E13.5 fetal liver Gsn(-/-) cells failed to undergo terminal maturation, a defect partially rescued by Cytochalasin D, and mimicked by administration of Jasplakinolide to the wild-type control samples.	jasplakinolide	188-202	gelsolin	Mus musculus	54-57
22331491-11	2012	Ethanol induced the endocytosis of VE-cadherin and the effect was blocked by jasplakinolide.	jasplakinolide	77-91	cadherin 5	Homo sapiens	35-46
22627736-6	2012	Pretreatment with jasplakinolide, an actin polymerizing agent, or a myosin heavy chain IIA (MHCIIA) blocker, blebbistatin, inhibited glucose-induced CD38 internalization, an essential step for cADPR formation.	jasplakinolide	18-32	CD38 molecule	Homo sapiens	149-153
21921266-7	2011	Exposure to actin-targeting drugs (Cytochalasin D, Latrunculin B, Jasplakinolide) for 24 hours led to disruption of alpha-SMA containing stress fibers.	jasplakinolide	66-80	actin gamma 2, smooth muscle	Rattus norvegicus	116-125
21757694-7	2011	Stabilization of the cytoskeleton with jasplakinolide abolished the inhibitory effects of cholesterol depletion on P2X1 receptor currents, suggesting that lipid rafts may regulate the receptor through stabilization of the cytoskeleton.	jasplakinolide	39-53	purinergic receptor P2X 1	Homo sapiens	115-128
21169791-12	2011	Isoflurane decreased drebrin immunofluorescence and enhanced cleaved caspase-3 in neurons, effects that were attenuated by pretreatment with either jasplakinolide (1 mum) or TAT-Pep5.	jasplakinolide	148-162	drebrin 1	Mus musculus	21-28
21738583-5	2011	In this study, we investigated the role of the F-actin cytoskeleton in the secretion of retinoschisin by treating Weri-Rb1 cells, which are known to secrete retinoschisin, with cytochalasin D, jasplakinolide, Y-27632, and dibutyryl cGMP.	jasplakinolide	193-207	retinoschisin 1	Homo sapiens	88-101
21738583-6	2011	Our results show that cytochalasin D and jasplakinolide inhibit retinoschisin secretion, whereas Y-27632 and dibutyryl cGMP enhance secretion causing F-actin alterations.	jasplakinolide	41-55	retinoschisin 1	Homo sapiens	64-77
20194498-13	2010	Strikingly, enriching the cortical cytoskeleton using jasplakinolide maintained raft probe co-clustering, CD45 exclusion, and Lck regulation in the IS following the addition of filipin.	jasplakinolide	54-68	protein tyrosine phosphatase receptor type C	Homo sapiens	106-110
20194498-13	2010	Strikingly, enriching the cortical cytoskeleton using jasplakinolide maintained raft probe co-clustering, CD45 exclusion, and Lck regulation in the IS following the addition of filipin.	jasplakinolide	54-68	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	126-129
19940153-8	2010	This behavior was enhanced in cells treated with jasplakinolide and was abrogated in a C-terminal truncated form (KCNQ1(R518X)-KCNE1) of the protein.	jasplakinolide	49-63	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	114-119
20181757-7	2010	Both the actin depolymerization drug latrunculin B and the actin stabilization drug jasplakinolide rapidly disrupted transport of secretory vesicles, but each drug caused distinct responses on different endosomal populations labeled by ARA6 or ARA7, indicating that a dynamic actin cytoskeleton was critical for some steps in endomembrane trafficking.	jasplakinolide	84-98	Ras-related small GTP-binding family protein	Arabidopsis thaliana	236-240
20181757-7	2010	Both the actin depolymerization drug latrunculin B and the actin stabilization drug jasplakinolide rapidly disrupted transport of secretory vesicles, but each drug caused distinct responses on different endosomal populations labeled by ARA6 or ARA7, indicating that a dynamic actin cytoskeleton was critical for some steps in endomembrane trafficking.	jasplakinolide	84-98	Ras-related small GTP-binding family protein	Arabidopsis thaliana	244-248
19940153-8	2010	This behavior was enhanced in cells treated with jasplakinolide and was abrogated in a C-terminal truncated form (KCNQ1(R518X)-KCNE1) of the protein.	jasplakinolide	49-63	potassium voltage-gated channel subfamily E regulatory subunit 1	Homo sapiens	127-132
19874818-9	2010	Latrunculin B (disrupting actin cytoskeleton) and jasplakinolide respectively suppressed and enhanced the expression of VSMC markers, SRF, myocardin, and CArG-box-mediated SMC promoters in PAC1, a VSMC line.	jasplakinolide	50-64	serum response factor	Homo sapiens	134-137
19874818-9	2010	Latrunculin B (disrupting actin cytoskeleton) and jasplakinolide respectively suppressed and enhanced the expression of VSMC markers, SRF, myocardin, and CArG-box-mediated SMC promoters in PAC1, a VSMC line.	jasplakinolide	50-64	dual specificity phosphatase 2	Homo sapiens	189-193
19290054-5	2009	Moreover, actin-associated AIP1 was rapidly abolished by jasplakinolide, which concurrently blocked the F-actin-cofilin interaction.	jasplakinolide	57-71	actin related protein T1	Homo sapiens	27-31
19339710-3	2009	We manipulated actin dynamics with jasplakinolide (100 nM) and latrunculin B (1 microM), both of which significantly inhibited the synthesis of decidualization markers induced by 6 days of treatment with embryo-mimicking stimulus interleukin 1beta (IL1B) and steroid hormones (SHs; 17beta-estradiol and medroxyprogesterone acetate) in the human uterine fibroblast (HuF) in vitro model.	jasplakinolide	35-49	interleukin 1 beta	Homo sapiens	230-247
19339710-3	2009	We manipulated actin dynamics with jasplakinolide (100 nM) and latrunculin B (1 microM), both of which significantly inhibited the synthesis of decidualization markers induced by 6 days of treatment with embryo-mimicking stimulus interleukin 1beta (IL1B) and steroid hormones (SHs; 17beta-estradiol and medroxyprogesterone acetate) in the human uterine fibroblast (HuF) in vitro model.	jasplakinolide	35-49	interleukin 1 beta	Homo sapiens	249-253
18760941-4	2009	RESULTS: Here we demonstrate that several CTGF/Cyr61/Nov (CCN) family members are differentially affected by either inhibition of actin polymerization (cytochalasin D treatment), promotion of actin polymerization (jasplakinolide treatment), inhibition of RhoA/rho kinase (ROCK) signaling (Y27632 treatment) and Rac1 signaling.	jasplakinolide	214-228	cellular communication network factor 2	Homo sapiens	42-46
18760941-4	2009	RESULTS: Here we demonstrate that several CTGF/Cyr61/Nov (CCN) family members are differentially affected by either inhibition of actin polymerization (cytochalasin D treatment), promotion of actin polymerization (jasplakinolide treatment), inhibition of RhoA/rho kinase (ROCK) signaling (Y27632 treatment) and Rac1 signaling.	jasplakinolide	214-228	cellular communication network factor 1	Homo sapiens	47-52
18760941-4	2009	RESULTS: Here we demonstrate that several CTGF/Cyr61/Nov (CCN) family members are differentially affected by either inhibition of actin polymerization (cytochalasin D treatment), promotion of actin polymerization (jasplakinolide treatment), inhibition of RhoA/rho kinase (ROCK) signaling (Y27632 treatment) and Rac1 signaling.	jasplakinolide	214-228	cellular communication network factor 3	Homo sapiens	53-56
19290054-5	2009	Moreover, actin-associated AIP1 was rapidly abolished by jasplakinolide, which concurrently blocked the F-actin-cofilin interaction.	jasplakinolide	57-71	cofilin 1	Homo sapiens	112-119
19290054-6	2009	Jasplakinolide also slowed dissociation of AIP1, which is analogous to the effect of this drug on capping protein.	jasplakinolide	0-14	actin related protein T1	Homo sapiens	43-47
18799653-5	2008	Higher concentrations of CB or Lat B, or stabilization of F-actin with jasplakinolide (JP), inhibited primary granule exocytosis measured as myeloperoxidase release but did not affect secondary granule exocytosis determined by lactoferrin release.	jasplakinolide	87-89	myeloperoxidase	Homo sapiens	141-156
18665919-5	2008	Translocation of Bid and Bax to the mitochondria was reduced by cytochalasin D, latrunculin A or jasplakinolide.	jasplakinolide	97-111	BH3 interacting domain death agonist	Homo sapiens	17-20
18665919-5	2008	Translocation of Bid and Bax to the mitochondria was reduced by cytochalasin D, latrunculin A or jasplakinolide.	jasplakinolide	97-111	BCL2 associated X, apoptosis regulator	Homo sapiens	25-28
18184743-12	2008	Instead, PTH perhaps initiates NPT2a endocytosis by inducing reorganization of the actin-containing microvilli in a process that is blocked by the actin-stabilizing compound jasplakinolide.	jasplakinolide	174-188	parathyroid hormone	Sus scrofa	9-12
18374641-6	2008	Conversely, Jasplakinolide treatment which increases stress fiber formation was able to mimic high frequency stretch-induced immobilisation of VEGF.	jasplakinolide	12-26	vascular endothelial growth factor A	Homo sapiens	143-147
18644792-5	2008	Electrotransjection of cells with anti-Orai1 antibody, directed toward the C-terminal region that mediates the interaction with STIM1, and stabilization of an actin cortical barrier with jasplakinolide prevented the interaction between STIM1 and hTRPC1.	jasplakinolide	187-201	stromal interaction molecule 1	Homo sapiens	236-241
18644792-5	2008	Electrotransjection of cells with anti-Orai1 antibody, directed toward the C-terminal region that mediates the interaction with STIM1, and stabilization of an actin cortical barrier with jasplakinolide prevented the interaction between STIM1 and hTRPC1.	jasplakinolide	187-201	transient receptor potential cation channel subfamily C member 1	Homo sapiens	246-252
18398002-2	2008	The actin-stabilizing toxin jasplakinolide (Jpk) induced, in a microtubule-dependent manner, a single, large F-actin aggregate, which contained beta- and gamma-actin, ADF/cofilin, cortactin, and the actin nucleator Arp2/3.	jasplakinolide	28-42	POTE ankyrin domain family member F	Homo sapiens	144-165
18398002-2	2008	The actin-stabilizing toxin jasplakinolide (Jpk) induced, in a microtubule-dependent manner, a single, large F-actin aggregate, which contained beta- and gamma-actin, ADF/cofilin, cortactin, and the actin nucleator Arp2/3.	jasplakinolide	28-42	destrin, actin depolymerizing factor	Homo sapiens	167-178
18398002-2	2008	The actin-stabilizing toxin jasplakinolide (Jpk) induced, in a microtubule-dependent manner, a single, large F-actin aggregate, which contained beta- and gamma-actin, ADF/cofilin, cortactin, and the actin nucleator Arp2/3.	jasplakinolide	28-42	cortactin	Homo sapiens	180-189
18398002-2	2008	The actin-stabilizing toxin jasplakinolide (Jpk) induced, in a microtubule-dependent manner, a single, large F-actin aggregate, which contained beta- and gamma-actin, ADF/cofilin, cortactin, and the actin nucleator Arp2/3.	jasplakinolide	28-42	actin related protein 2	Homo sapiens	215-219
19521476-4	2006	By contrast, drug-induced stimulation of actin polymerization and inhibition of actin turnover, using two different agents phalloidin and jasplakinolide, compromised the root gravibending.	jasplakinolide	138-152	actin-7	Zea mays	80-85
17651738-3	2007	Either the actin-stabilizing jasplakinolide or the actin-depolymerising latrunculin B variably but significantly inhibited post-Golgi traffic of non-raft associated apical p75NTR and basolateral VSV-G cargoes.	jasplakinolide	29-43	nerve growth factor receptor	Homo sapiens	172-178
17507430-7	2007	Stabilization of actin filaments with jasplakinolide, in unstretched portal veins, resulted in increased ERK phosphorylation and global protein synthesis as well as the synthesis of contractile proteins.	jasplakinolide	38-52	mitogen-activated protein kinase 1	Homo sapiens	105-108
17332502-4	2007	A dramatic reduction of actin filament bundles is observed in ALP-antisense cells and treatment of these cells with the actin-stabilizing drug jasplakinolide stimulates SRF activity and restores the capacity of the cells to differentiate.	jasplakinolide	143-157	ATHS	Homo sapiens	62-65
17332502-4	2007	A dramatic reduction of actin filament bundles is observed in ALP-antisense cells and treatment of these cells with the actin-stabilizing drug jasplakinolide stimulates SRF activity and restores the capacity of the cells to differentiate.	jasplakinolide	143-157	serum response factor	Homo sapiens	169-172
17223073-5	2007	The F-actin-severing compounds, latrunculin and cytochalasin, significantly increased PTH secretion, while the actin polymerizing agent, jasplakinolide, substantially inhibited PTH secretion.	jasplakinolide	137-151	parathyroid hormone	Homo sapiens	177-180
17218416-3	2007	In the current study, GnRH caused acute and dramatic changes in cellular morphology in the gonadotrope-derived alphaT3-1 cell line, which appeared to be mediated by engagement of the actin cytoskeleton; disruption of actin with jasplakinolide abrogated cell movement and GnRH-induced activation of ERK.	jasplakinolide	228-242	gonadotropin releasing hormone 1	Mus musculus	22-26
16461348-9	2006	Finally, treatment with jasplakinolide, an inhibitor of actin turnover, resulted in dose-dependent inhibition of beta(2)AR internalization, suggesting that turnover of actin filaments at the receptor complex is required for endocytosis.	jasplakinolide	24-38	adrenoceptor beta 2	Homo sapiens	113-122
16565484-6	2006	The F-actin stabilizer jasplakinolide prevented both ZO-1 redistribution and albumin leakage, suggesting that actin cytoskeleton rearrangement is instrumental to podocyte permselective dysfunction induced by Ang II.	jasplakinolide	23-37	tight junction protein 1	Rattus norvegicus	53-57
16565484-6	2006	The F-actin stabilizer jasplakinolide prevented both ZO-1 redistribution and albumin leakage, suggesting that actin cytoskeleton rearrangement is instrumental to podocyte permselective dysfunction induced by Ang II.	jasplakinolide	23-37	angiotensinogen	Rattus norvegicus	208-214
16417946-8	2006	On the contrary, a small, but significant, increase of EAAT3 activity was observed upon incubation with jasplakinolide, a drug that stabilizes actin microfilaments.	jasplakinolide	104-118	solute carrier family 1 member 1	Rattus norvegicus	55-60
16113046-9	2006	Moreover, PAEC incubation with cytochalasin D and jasplakinolide resulted in increases in eNOS/actin association and in eNOS activity without changes in eNOS protein content.	jasplakinolide	50-64	nitric oxide synthase 3	Homo sapiens	90-94
16113046-9	2006	Moreover, PAEC incubation with cytochalasin D and jasplakinolide resulted in increases in eNOS/actin association and in eNOS activity without changes in eNOS protein content.	jasplakinolide	50-64	nitric oxide synthase 3	Homo sapiens	120-124
16113046-9	2006	Moreover, PAEC incubation with cytochalasin D and jasplakinolide resulted in increases in eNOS/actin association and in eNOS activity without changes in eNOS protein content.	jasplakinolide	50-64	nitric oxide synthase 3	Homo sapiens	120-124
15703216-10	2005	FM4-64 was endocytosed in nontransgenic root hairs treated with the actin-stabilizing drug jasplakinolide.	jasplakinolide	91-105	actin-12	Arabidopsis thaliana	68-73
15920016-8	2005	Unexpectedly, RhoV14, RacV12, and jasplakinolide all increased amylase secretion by CCK from 30 pM to 10 nM.	jasplakinolide	34-48	cholecystokinin	Mus musculus	84-87
15855633-6	2005	Both Y27632, which inhibits Rho kinase-dependent stress fiber formation, and jasplakinolide, an F-actin stabilizer, decreased NF-kappaB and Ap-1 activity and reduced ET-1 expression.	jasplakinolide	77-91	jun proto-oncogene	Mus musculus	140-144
15855633-6	2005	Both Y27632, which inhibits Rho kinase-dependent stress fiber formation, and jasplakinolide, an F-actin stabilizer, decreased NF-kappaB and Ap-1 activity and reduced ET-1 expression.	jasplakinolide	77-91	endothelin 1	Mus musculus	166-170
16219977-11	2005	Jasplakinolide, an actin-stabilizing drug, alone induced actin polymerization in the extracts and lead to dephosphorylation of ADF/cofilin.	jasplakinolide	0-14	gelsolin S homeolog	Xenopus laevis	127-138
15644322-4	2005	Jasplakinolide, which stabilizes F-actin, or latrunculin B, which disrupts F-actin, decreased basal HCO3- absorption by 30% and prevented the inhibition by amiloride or NGF.	jasplakinolide	0-14	nerve growth factor	Rattus norvegicus	169-172
15665004-8	2005	Both inhibition of actin polymerization by cytochalasin D and stabilization of existing actin filaments by jasplakinolide resulted in increased Sox9 mRNA levels, whereas inhibition of microtubule polymerization by colchicine completely blocked Sox9 expression.	jasplakinolide	107-121	SRY-box transcription factor 9	Homo sapiens	144-148
15492012-5	2005	Inhibition of arsenic-induced actin filament reorganization by either overexpression of a dominant negative Cdc42 or pretreatment of an actin filament stabilizing regent, jasplakinolide, abrogated arsenic-induced NADPH oxidase activation, showing that the activation of NADPH oxidase was regulated by Cdc42-mediated actin filament reorganization.	jasplakinolide	171-185	cell division cycle 42	Mus musculus	301-306
15591047-8	2005	When jasplakinolide was used to overcome the severing action of gelsolin by polymerizing actin, complete inhibition of the alkaline pH- and cAMP-induced apical membrane accumulation of V-ATPase was observed.	jasplakinolide	5-19	gelsolin	Homo sapiens	64-72
15652551-4	2005	Actin-specific agents, including latrunculin A and jasplakinolide, are used to alter the organization of the cytoskeletal actin.	jasplakinolide	51-65	actin-2	Brassica oleracea	0-5
15652551-4	2005	Actin-specific agents, including latrunculin A and jasplakinolide, are used to alter the organization of the cytoskeletal actin.	jasplakinolide	51-65	actin-2	Brassica oleracea	122-127
15509657-6	2005	Jasplakinolide, a drug that prevents actin filament disassembly, counteracts the effect of IGF-I on integrin-mediated cell adhesion.	jasplakinolide	0-14	insulin like growth factor 1	Homo sapiens	91-96
15581426-12	2004	The sensitivity of leptin and insulin stimulation of KATP channel opening in arcuate neurones to jasplakinolide indicates that cytoskeletal remodelling may be an important contributor to the cellular signalling mechanisms of these hormones in hypothalamic neurones.	jasplakinolide	97-111	leptin	Mus musculus	19-25
15128868-8	2004	Jasplakinolide, which stabilizes actin filaments, produced PLFs with more open substructure including individual filaments with evenly-spaced rows of radially projecting short filaments.	jasplakinolide	0-14	actin like 6A S homeolog	Xenopus laevis	33-38
15466888-8	2004	Latrunculin B, cytochalasin D and jasplakinolide, which disrupt actin dynamics, prevented insulin- and PDGF-induced actin remodeling but significantly inhibited GLUT4myc translocation only in response to insulin (75-85%, P<0.05), not to PDGF (20-30% inhibition).	jasplakinolide	34-48	insulin	Homo sapiens	90-97
15466888-8	2004	Latrunculin B, cytochalasin D and jasplakinolide, which disrupt actin dynamics, prevented insulin- and PDGF-induced actin remodeling but significantly inhibited GLUT4myc translocation only in response to insulin (75-85%, P<0.05), not to PDGF (20-30% inhibition).	jasplakinolide	34-48	solute carrier family 2 member 4	Homo sapiens	161-166
15466888-8	2004	Latrunculin B, cytochalasin D and jasplakinolide, which disrupt actin dynamics, prevented insulin- and PDGF-induced actin remodeling but significantly inhibited GLUT4myc translocation only in response to insulin (75-85%, P<0.05), not to PDGF (20-30% inhibition).	jasplakinolide	34-48	insulin	Homo sapiens	204-211
15240009-9	2004	Treatment of OVCAR-3 cells with the F-actin stabilizing compound, jasplakinolide, prevented the protein kinase A (PKA)-mediated inhibition of SRF.	jasplakinolide	66-80	serum response factor	Homo sapiens	142-145
15456825-10	2004	The CA-Abl phenotype is not affected by destabilization of microtubules but is reversed partially when actin filaments are stabilized with jasplakinolide.	jasplakinolide	139-153	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	7-10
15030313-5	2004	In contrast, F-actin stabilization by jasplakinolide, which redistributed cortactin to F-actin-containing patches, prevented cortactin phosphorylation triggered by hypertonic stress or LB.	jasplakinolide	38-52	cortactin	Homo sapiens	74-83
15030313-5	2004	In contrast, F-actin stabilization by jasplakinolide, which redistributed cortactin to F-actin-containing patches, prevented cortactin phosphorylation triggered by hypertonic stress or LB.	jasplakinolide	38-52	cortactin	Homo sapiens	125-134
15184395-8	2004	Induction of actin polymerization by jasplakinolide increased SM22alpha synthesis in unstretched veins to the level in stretched veins.	jasplakinolide	37-51	transgelin	Mus musculus	62-71
15194790-3	2004	Disrupting actin filament dynamics with jasplakinolide or latrunculin A arrested fusion at a late step in the formation of Env-CD4-coreceptor complexes.	jasplakinolide	40-54	endogenous retrovirus group K member 20	Homo sapiens	123-126
15034928-6	2004	A functioning actin cytoskeleton was important for VCAM-1 and ICAM-1 expression as both cytochalasin D, an actin filament disruptor, and jasplakinolide, an actin filament stabilizer, attenuated the expression of these CAMs.	jasplakinolide	137-151	vascular cell adhesion molecule 1	Homo sapiens	51-57
15034928-6	2004	A functioning actin cytoskeleton was important for VCAM-1 and ICAM-1 expression as both cytochalasin D, an actin filament disruptor, and jasplakinolide, an actin filament stabilizer, attenuated the expression of these CAMs.	jasplakinolide	137-151	intercellular adhesion molecule 1	Homo sapiens	62-68
14517310-4	2003	These transient snarls and internal bundles can be stabilized by culturing elongating bristles with jasplakinolide, a membrane-permeant inhibitor of actin filament depolymerization, resulting in enormous numbers of internal bundles and uncross-linked filaments.	jasplakinolide	100-114	Actin 79B	Drosophila melanogaster	149-154
14660592-9	2004	Agents that modulate the actin cytoskeleton (cytochalasin D and jasplakinolide) altered the plasma membrane mobility of CFTR but not CFTR- DeltaTRL.	jasplakinolide	64-78	CF transmembrane conductance regulator	Canis lupus familiaris	120-124
12869574-5	2003	The inhibitory effects of latrunculin B and jasplakinolide, and of nocodazole and colchicine, respectively, revealed a requirement for both the actin and microtubule cytoskeletons in GLUT1 translocation and transport stimulation.	jasplakinolide	44-58	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	183-188
12616543-8	2003	As with jasplakinolide, the enhancement of commitment to apoptosis could be delayed by overexpression of the anti-apoptotic protein Bcl-x(L), but, unlike jasplakinolide, cytochalasin D modestly affected the "execution" stage of apoptosis as well.	jasplakinolide	8-22	BCL2 like 1	Homo sapiens	132-137
12777392-13	2003	Actin cytoskeletal disruption with cytochalasin-D also prevented stretch from increasing nuclear ERK, whereas actin polymerization with jasplakinolide restored nuclear translocation of activated ERK in the presence of MbetaCD.	jasplakinolide	136-150	Eph receptor B1	Rattus norvegicus	195-198
12799187-4	2003	Accordingly, direct disruption of the actin cytoskeleton by cytochalasin D, latrunculin B, or jasplakinolide enhanced cytokine-induced iNOS expression.	jasplakinolide	94-108	nitric oxide synthase 2	Homo sapiens	135-139
12514193-1	2003	In cultured chick ciliary neurons, when ATP synthesis is inhibited, ATP depletion is reduced approximately 50% by slowing actin filament turnover with jasplakinolide or latrunculin A.	jasplakinolide	151-165	actin, beta	Gallus gallus	122-127
12595338-7	2003	Moreover, PAR2-like PAR1-stimulated exocytosis requires actin cytoskeleton remodeling, because vWF release is inhibited if the cells were pretreated with Jasplakinolide.	jasplakinolide	154-168	von Willebrand factor	Homo sapiens	95-98
12595338-7	2003	Moreover, PAR2-like PAR1-stimulated exocytosis requires actin cytoskeleton remodeling, because vWF release is inhibited if the cells were pretreated with Jasplakinolide.	jasplakinolide	154-168	F2R like trypsin receptor 1	Homo sapiens	10-14
12595338-7	2003	Moreover, PAR2-like PAR1-stimulated exocytosis requires actin cytoskeleton remodeling, because vWF release is inhibited if the cells were pretreated with Jasplakinolide.	jasplakinolide	154-168	Prader Willi/Angelman region RNA 1	Homo sapiens	20-24
12586371-6	2003	The response to sulphatides was inhibited by jasplakinolide, an actin-polymerising agent known to downregulate surface expression of L-selectin, Fc gamma RIIIb, CD43 and CD44.	jasplakinolide	45-59	selectin L	Homo sapiens	133-143
12586371-6	2003	The response to sulphatides was inhibited by jasplakinolide, an actin-polymerising agent known to downregulate surface expression of L-selectin, Fc gamma RIIIb, CD43 and CD44.	jasplakinolide	45-59	Fc gamma receptor IIIb	Homo sapiens	145-159
12586371-6	2003	The response to sulphatides was inhibited by jasplakinolide, an actin-polymerising agent known to downregulate surface expression of L-selectin, Fc gamma RIIIb, CD43 and CD44.	jasplakinolide	45-59	sialophorin	Homo sapiens	161-165
12586371-6	2003	The response to sulphatides was inhibited by jasplakinolide, an actin-polymerising agent known to downregulate surface expression of L-selectin, Fc gamma RIIIb, CD43 and CD44.	jasplakinolide	45-59	CD44 molecule (Indian blood group)	Homo sapiens	170-174
12388079-3	2003	Stabilization of actin polymerization with jasplakinolide increased activity of NKCC1, whereas inhibition of actin polymerization with latrunculin B prevented hormonal activation of NKCC1.	jasplakinolide	43-57	solute carrier family 12 member 2	Homo sapiens	80-85
12514193-2	2003	Jasplakinolide inhibits actin disassembly, and latrunculin A prevents actin assembly by sequestering actin monomers.	jasplakinolide	0-14	actin, beta	Gallus gallus	24-29
11907284-9	2002	Surprisingly, jasplakinolide also affects myosin, inducing the formation of short rods throughout the cytoplasm.	jasplakinolide	14-28	myosin heavy chain 14	Homo sapiens	42-48
12107059-8	2002	Depolymerization of actin increased endocytosis of E-cadherin, whereas the PKC-induced uptake of E-cadherin was blocked by the actin stabilizer jasplakinolide.	jasplakinolide	144-158	cadherin 1	Canis lupus familiaris	97-107
12363040-0	2002	Induction of apoptosis and CD10/neutral endopeptidase expression by jaspamide in HL-60 line cells.	jasplakinolide	68-77	membrane metalloendopeptidase	Homo sapiens	27-31
12363040-0	2002	Induction of apoptosis and CD10/neutral endopeptidase expression by jaspamide in HL-60 line cells.	jasplakinolide	68-77	membrane metalloendopeptidase	Homo sapiens	32-53
12363040-2	2002	We characterized the jasplakinolide-induced loss of viability by programmed cell death in the HL-60 human promyelocytic leukemia cell line and found that this process was accompanied by neutral endopeptidase (NEP)/CD10 expression on the surface of the apoptotic cells.	jasplakinolide	21-35	membrane metalloendopeptidase	Homo sapiens	186-207
12363040-2	2002	We characterized the jasplakinolide-induced loss of viability by programmed cell death in the HL-60 human promyelocytic leukemia cell line and found that this process was accompanied by neutral endopeptidase (NEP)/CD10 expression on the surface of the apoptotic cells.	jasplakinolide	21-35	membrane metalloendopeptidase	Homo sapiens	209-212
12363040-2	2002	We characterized the jasplakinolide-induced loss of viability by programmed cell death in the HL-60 human promyelocytic leukemia cell line and found that this process was accompanied by neutral endopeptidase (NEP)/CD10 expression on the surface of the apoptotic cells.	jasplakinolide	21-35	membrane metalloendopeptidase	Homo sapiens	214-218
12363040-3	2002	HL-60 cells do not normally express detectable amounts of NEP/CD10 on their surface or intracytoplasmically, but upon jaspamide treatment, CD10 was synthesized de novo, its expression being inhibited by cycloheximide pretreatment.	jasplakinolide	118-127	membrane metalloendopeptidase	Homo sapiens	139-143
12363040-4	2002	Once synthesized, NEP/CD10 interfered with the jasplakinolide signal delivered to HL-60 cells.	jasplakinolide	47-61	membrane metalloendopeptidase	Homo sapiens	18-21
12363040-4	2002	Once synthesized, NEP/CD10 interfered with the jasplakinolide signal delivered to HL-60 cells.	jasplakinolide	47-61	membrane metalloendopeptidase	Homo sapiens	22-26
12363040-9	2002	Our findings suggest that the CD10 expression is related to the programmed cell death induction by jaspamide, and also with the process of granulocytic differentiation in HL-60 cells.	jasplakinolide	99-108	membrane metalloendopeptidase	Homo sapiens	30-34
12358800-6	2002	Cytochalasin D attenuated, while jasplakinolide augmented, thapsigargin-induced JNK activation and neuronal cell death.	jasplakinolide	33-47	mitogen-activated protein kinase 8	Homo sapiens	80-83
12099217-0	2002	Jasplakinolide reversibly disrupts actin filaments in suspension-cultured tobacco BY-2 cells.	jasplakinolide	0-14	actin	Nicotiana tabacum	35-40
12099217-1	2002	Jasplakinolide is potentially a useful pharmacological tool for the study of actin organization and dynamics in living cells, since it induces actin polymerization in vitro and, unlike phalloidin, is membrane permeative.	jasplakinolide	0-14	actin	Nicotiana tabacum	77-82
12099217-1	2002	Jasplakinolide is potentially a useful pharmacological tool for the study of actin organization and dynamics in living cells, since it induces actin polymerization in vitro and, unlike phalloidin, is membrane permeative.	jasplakinolide	0-14	actin	Nicotiana tabacum	143-148
12099217-2	2002	In the present work, the effect of jasplakinolide on the actin cytoskeleton of living suspension-cultured Nicotiana tabacum "Bright Yellow 2" cells was investigated.	jasplakinolide	35-49	actin	Nicotiana tabacum	57-62
12099217-3	2002	Actin filaments in the living cells were disrupted by jasplakinolide.	jasplakinolide	54-68	actin	Nicotiana tabacum	0-5
12099217-5	2002	When cells were treated with a moderate concentration (150 nM) of jasplakinolide, cortical actin filaments were disrupted preferentially, whereas actin aggregated at the perinuclear region.	jasplakinolide	66-80	actin	Nicotiana tabacum	91-96
12099217-5	2002	When cells were treated with a moderate concentration (150 nM) of jasplakinolide, cortical actin filaments were disrupted preferentially, whereas actin aggregated at the perinuclear region.	jasplakinolide	66-80	actin	Nicotiana tabacum	146-151
12099217-7	2002	The effect of jasplakinolide on the actin cytoskeleton was reversible even at high concentration.	jasplakinolide	14-28	actin	Nicotiana tabacum	36-41
12196544-6	2002	Inhibition of IP(3) recycling using Li(+) or inhibition of IP(3)Rs with xestospongin C or treatment with jasplakinolide, to stabilize the cortical actin filament network, abolished thrombin-induced coupling between hTrp1 and IP(3)R type II.	jasplakinolide	105-119	coagulation factor II, thrombin	Homo sapiens	181-189
11524429-6	2001	Jasplakinolide also induced internalization of Trp3 and caveolin-1.	jasplakinolide	0-14	transient receptor potential cation channel subfamily C member 3	Homo sapiens	47-51
11810694-9	2002	Further, increasing or decreasing cellular G-actin concentration by treating live cells with latrunculin-A or jasplakinolide, respectively, caused a respective increase and decrease in DNase I cell-staining intensity as expected.	jasplakinolide	110-124	deoxyribonuclease 1	Homo sapiens	185-192
11524429-6	2001	Jasplakinolide also induced internalization of Trp3 and caveolin-1.	jasplakinolide	0-14	caveolin 1	Homo sapiens	56-66
11522794-8	2001	In contrast, involvement of actin in the effect of cAMP on the exchanger is supported by the following observations: (i) jasplakinolide, an F-actin stabilizer, prevents the inhibition caused by forskolin, and (ii) constitutively active forms of RhoA and Rho kinase interfere with actin disruption by forskolin and also decrease inhibition of the transporter.	jasplakinolide	121-135	transforming protein RhoA	Cricetulus griseus	245-249
10984494-10	2000	Jasplakinolide prevented the inhibitory effect of 8-Br-cGMP on activated ERK nuclear translocation after strain.	jasplakinolide	0-14	mitogen-activated protein kinase 1	Homo sapiens	73-76
11502570-5	2001	Jasplakinolide (Jasp), which binds to and stabilizes F-actin, suppressed iNOS expression enhanced by LatB.	jasplakinolide	0-14	nitric oxide synthase 2	Homo sapiens	73-77
11502570-5	2001	Jasplakinolide (Jasp), which binds to and stabilizes F-actin, suppressed iNOS expression enhanced by LatB.	jasplakinolide	0-4	nitric oxide synthase 2	Homo sapiens	73-77
11259397-10	2001	Jasplakinolide, an actin polymerizing agent, mimics the synergistic effect of RhoA and beta1 integrin on the actin promoter.	jasplakinolide	0-14	ras homolog family member A	Homo sapiens	78-82
11259397-10	2001	Jasplakinolide, an actin polymerizing agent, mimics the synergistic effect of RhoA and beta1 integrin on the actin promoter.	jasplakinolide	0-14	integrin subunit beta 1	Homo sapiens	87-101
11035001-5	2001	In contrast, increasing actin polymerization with jasplakinolide (0.5 microm) increased SM22 and SM alpha-actin promoter activity by 22-fold and 13-fold, respectively.	jasplakinolide	50-64	transgelin	Rattus norvegicus	88-92
11489930-7	2001	GLUT4myc externalization and membrane ruffles were reduced by jasplakinolide and by swinholide-A, drugs that affect actin filament stability and prevent actin branching, respectively.	jasplakinolide	62-76	solute carrier family 2 member 4	Homo sapiens	0-5
11278342-5	2001	Although LPL and ligand showed synergy for ligand-induced binding site expression when actin depolymerization was inhibited by jasplakinolide, LPL peptide-induced adhesion was inhibited.	jasplakinolide	127-141	lymphocyte cytosolic protein 1	Homo sapiens	9-12
11238018-6	2001	Jasplakinolide (1 nM to 1 microM), a polymerizing agent for microfilaments, decreased LPS-induced MIP-2 secretion.	jasplakinolide	0-14	C-X-C motif chemokine ligand 2	Rattus norvegicus	98-103
10704376-6	2000	Interestingly, inhibitors of actin filament assembly (cytochalasin D and latrunculin A) dramatically curtailed bristle elongation while a filament stabilizer (jasplakinolide) accelerated elongation.	jasplakinolide	159-173	Actin 79B	Drosophila melanogaster	29-34
11137010-3	2000	Jasplakinolide is the only readily available drug that stabilises F-actin structures both in vivo and in vitro [3-6].	jasplakinolide	0-14	actin	Saccharomyces cerevisiae S288C	68-73
11137010-5	2000	Treatment of these cells with jasplakinolide caused rapid and dramatic effects on the actin cytoskeleton, resulting in the accumulation of single large actin structures in cells.	jasplakinolide	30-44	actin	Saccharomyces cerevisiae S288C	86-91
11137010-5	2000	Treatment of these cells with jasplakinolide caused rapid and dramatic effects on the actin cytoskeleton, resulting in the accumulation of single large actin structures in cells.	jasplakinolide	30-44	actin	Saccharomyces cerevisiae S288C	152-157
10828033-6	2000	The authors previously observed that actin stabilization by the cell permeant agent jasplakinolide enhanced cell death upon interleukin (IL)-2 or IL-3 withdrawal from growth-factor-dependent lymphocyte cell lines, and hypothesized that actin polymerization could alter the activity of gelsolin, thus enhancing apoptosis.	jasplakinolide	84-98	interleukin 3	Homo sapiens	146-150
10828033-6	2000	The authors previously observed that actin stabilization by the cell permeant agent jasplakinolide enhanced cell death upon interleukin (IL)-2 or IL-3 withdrawal from growth-factor-dependent lymphocyte cell lines, and hypothesized that actin polymerization could alter the activity of gelsolin, thus enhancing apoptosis.	jasplakinolide	84-98	gelsolin	Homo sapiens	285-293
10893189-4	2000	If treated with jasplakinolide after fMLP, the cells stopped migrating but could not detach when fMLP was removed.	jasplakinolide	16-30	formyl peptide receptor 1	Homo sapiens	37-41
10893189-4	2000	If treated with jasplakinolide after fMLP, the cells stopped migrating but could not detach when fMLP was removed.	jasplakinolide	16-30	formyl peptide receptor 1	Homo sapiens	97-101
11154977-2	2000	Jaspamide at 5 x 10(-8) M concentration exhibited antiproliferative activity and an increased CD4 and CD14 surface expression.	jasplakinolide	0-9	CD4 molecule	Homo sapiens	94-97
10652253-5	2000	The "gap" did not disappear when cells were treated with the actin stabilizing drug jasplakinolide.	jasplakinolide	84-98	Actin 79B	Drosophila melanogaster	61-66
11154977-2	2000	Jaspamide at 5 x 10(-8) M concentration exhibited antiproliferative activity and an increased CD4 and CD14 surface expression.	jasplakinolide	0-9	CD14 molecule	Homo sapiens	102-106
10580995-3	1999	The level of full-length beta-actin mRNA in cells was reduced when actin filaments were depolymerized by treatment with latrunculin A and elevated when actin polymerization was induced by jasplakinolide.	jasplakinolide	188-202	POTE ankyrin domain family member F	Homo sapiens	25-35
9788576-4	1998	RESULTS: Jasplakinolide was cytotoxic toward human prostate carcinoma cells, DU-145, PC-3 and LNCaP in culture, killing 1 log of cells with 0.8, 0.3 and 0.07 microM of drug in 24 h, respectively.	jasplakinolide	9-23	chromobox 8	Homo sapiens	85-89
10531004-0	1999	Role of actin-filament disassembly in lamellipodium protrusion in motile cells revealed using the drug jasplakinolide.	jasplakinolide	103-117	actin, beta	Gallus gallus	8-13
10531004-2	1999	The importance of actin-filament disassembly in this process is less well understood, and is assessed here using the actin drug jasplakinolide, which has two known activities - inhibition of filament disassembly and induction of an increase in actin polymer.	jasplakinolide	128-142	actin, beta	Gallus gallus	18-23
10531004-2	1999	The importance of actin-filament disassembly in this process is less well understood, and is assessed here using the actin drug jasplakinolide, which has two known activities - inhibition of filament disassembly and induction of an increase in actin polymer.	jasplakinolide	128-142	actin, beta	Gallus gallus	117-122
10531004-2	1999	The importance of actin-filament disassembly in this process is less well understood, and is assessed here using the actin drug jasplakinolide, which has two known activities - inhibition of filament disassembly and induction of an increase in actin polymer.	jasplakinolide	128-142	actin, beta	Gallus gallus	117-122
10531004-3	1999	RESULTS: In cells the two activities of jasplakinolide were found to be separable; 1 microM jasplakinolide could permeate cells, bind cellular filamentous actin (F-actin) and inhibit filament disassembly within 3.5 minutes, but significant increase in actin polymer was not detected until 60 minutes of treatment.	jasplakinolide	40-54	actin, beta	Gallus gallus	155-160
10531004-3	1999	RESULTS: In cells the two activities of jasplakinolide were found to be separable; 1 microM jasplakinolide could permeate cells, bind cellular filamentous actin (F-actin) and inhibit filament disassembly within 3.5 minutes, but significant increase in actin polymer was not detected until 60 minutes of treatment.	jasplakinolide	40-54	actin, beta	Gallus gallus	164-169
10531004-3	1999	RESULTS: In cells the two activities of jasplakinolide were found to be separable; 1 microM jasplakinolide could permeate cells, bind cellular filamentous actin (F-actin) and inhibit filament disassembly within 3.5 minutes, but significant increase in actin polymer was not detected until 60 minutes of treatment.	jasplakinolide	40-54	actin, beta	Gallus gallus	164-169
10531004-3	1999	RESULTS: In cells the two activities of jasplakinolide were found to be separable; 1 microM jasplakinolide could permeate cells, bind cellular filamentous actin (F-actin) and inhibit filament disassembly within 3.5 minutes, but significant increase in actin polymer was not detected until 60 minutes of treatment.	jasplakinolide	92-106	actin, beta	Gallus gallus	155-160
10531004-3	1999	RESULTS: In cells the two activities of jasplakinolide were found to be separable; 1 microM jasplakinolide could permeate cells, bind cellular filamentous actin (F-actin) and inhibit filament disassembly within 3.5 minutes, but significant increase in actin polymer was not detected until 60 minutes of treatment.	jasplakinolide	92-106	actin, beta	Gallus gallus	164-169
10531004-3	1999	RESULTS: In cells the two activities of jasplakinolide were found to be separable; 1 microM jasplakinolide could permeate cells, bind cellular filamentous actin (F-actin) and inhibit filament disassembly within 3.5 minutes, but significant increase in actin polymer was not detected until 60 minutes of treatment.	jasplakinolide	92-106	actin, beta	Gallus gallus	164-169
10491398-9	1999	Interestingly, broad-spectrum inhibitors of protein tyrosine kinases (genistein) and protein tyrosine phosphatases (orthovanadate), and actin filament stabilizing compound (jasplakinolide), also block protrusive activity of the Matrigel-embedded cells but have no effect on the production of MMP-2.	jasplakinolide	173-187	matrix metallopeptidase 2	Homo sapiens	292-297
10464255-3	1999	By contrast, stabilizing actin filaments with jasplakinolide prevented cytochalasin D-, latrunculin A-, and ADP-induced fibrinogen binding.	jasplakinolide	46-60	fibrinogen beta chain	Homo sapiens	120-130
10484469-5	1999	In fact, LPS-induced TNF-alpha production was further enhanced by CytoD (1-10 microM) and inhibited by jasplakinolide, a polymerizing agent for microfilaments.	jasplakinolide	103-117	tumor necrosis factor	Rattus norvegicus	21-30
10339509-4	1999	In addition, 10(-7) mol/L jaspamide induced maturation of HL-60 cells as indicated by the appearance of a lobulated nucleus in 55% +/- 5% of the cells and immunophenotypic maturation of the leukemia cells (upregulation of CD16 and CD14 B antigens).	jasplakinolide	26-35	Fc gamma receptor IIIa	Homo sapiens	222-226
10339509-4	1999	In addition, 10(-7) mol/L jaspamide induced maturation of HL-60 cells as indicated by the appearance of a lobulated nucleus in 55% +/- 5% of the cells and immunophenotypic maturation of the leukemia cells (upregulation of CD16 and CD14 B antigens).	jasplakinolide	26-35	CD14 molecule	Homo sapiens	231-235
10049751-5	1999	To establish a role for the actin cytoskeleton in the control of FcgammaRIIIb shedding, we treated human neutrophils with jasplakinolide, an actin-polymerizing peptide.	jasplakinolide	122-136	Fc gamma receptor IIIb	Homo sapiens	65-77
9788576-6	1998	In combination with radiation, jasplakinolide produced some diminution in the shoulder of the survival curve of normally oxygenated PC-3 cells and was a radiation sensitizer of hypoxic DU-145 cells and hypoxic PC-3 cells.	jasplakinolide	31-45	chromobox 8	Homo sapiens	132-136
9788576-6	1998	In combination with radiation, jasplakinolide produced some diminution in the shoulder of the survival curve of normally oxygenated PC-3 cells and was a radiation sensitizer of hypoxic DU-145 cells and hypoxic PC-3 cells.	jasplakinolide	31-45	chromobox 8	Homo sapiens	210-214
9325191-5	1997	Pretreatment with jasplakinolide also blocked de novo expression of integrin CD11b and shape change which otherwise occurred in minutes after treatment with fMLP.	jasplakinolide	18-32	integrin subunit alpha M	Homo sapiens	77-82
9325191-5	1997	Pretreatment with jasplakinolide also blocked de novo expression of integrin CD11b and shape change which otherwise occurred in minutes after treatment with fMLP.	jasplakinolide	18-32	formyl peptide receptor 1	Homo sapiens	157-161
33036756-5	2021	Interestingly, the WHAMM actin binding deficit could be rescued with pharmacologic induction of actin polymerization in SETD2-null cells using Jasplakinolide.	jasplakinolide	143-157	WASP homolog associated with actin, golgi membranes and microtubules	Homo sapiens	19-24
8661226-11	1996	FAK phosphorylation was inhibited to near-basal levels (50% of bombesin stimulated) by 500 nM Jas (63%) and 500 nM CyE (61%).	jasplakinolide	94-97	protein tyrosine kinase 2	Homo sapiens	0-3
8661226-11	1996	FAK phosphorylation was inhibited to near-basal levels (50% of bombesin stimulated) by 500 nM Jas (63%) and 500 nM CyE (61%).	jasplakinolide	94-97	gastrin releasing peptide	Homo sapiens	63-71
8661226-13	1996	Jasplakinolide, which induced over-polymerization of actin, and CyE, which depolymerizes actin, both inhibited bombesin-stimulated phosphorylation of FAK and inhibited PC-3 cell growth.	jasplakinolide	0-14	gastrin releasing peptide	Homo sapiens	111-119
8661226-13	1996	Jasplakinolide, which induced over-polymerization of actin, and CyE, which depolymerizes actin, both inhibited bombesin-stimulated phosphorylation of FAK and inhibited PC-3 cell growth.	jasplakinolide	0-14	protein tyrosine kinase 2	Homo sapiens	150-153
7601248-7	1995	In addition, Jaspamide, similarly to ARA-C, was able to induce immunophenotypic maturation of leukemic cell lines (upregulation of CD14 and CD11 and downregulation of CD34 antigens).	jasplakinolide	13-22	CD14 molecule	Homo sapiens	131-135
7601248-7	1995	In addition, Jaspamide, similarly to ARA-C, was able to induce immunophenotypic maturation of leukemic cell lines (upregulation of CD14 and CD11 and downregulation of CD34 antigens).	jasplakinolide	13-22	CD34 molecule	Homo sapiens	167-171
7666463-3	1995	The growth-inhibitory effect of jasplakinolide on the PC-3 cell line was studied in detail to elucidate its mechanism of action.	jasplakinolide	32-46	proprotein convertase subtilisin/kexin type 1	Homo sapiens	54-58
7666463-9	1995	RESULTS: The growth of PC-3, LNCaP, and TSU-Pr1 cells was potently inhibited by exposure to jasplakinolide for 48 hours; doses of jasplakinolide that led to 50% growth inhibition were 65 nM for PC-3 cells, 41 nM for LNCaP cells, and 170 nM for TSU-Pr1 cells.	jasplakinolide	92-106	proprotein convertase subtilisin/kexin type 1	Homo sapiens	23-27
7666463-9	1995	RESULTS: The growth of PC-3, LNCaP, and TSU-Pr1 cells was potently inhibited by exposure to jasplakinolide for 48 hours; doses of jasplakinolide that led to 50% growth inhibition were 65 nM for PC-3 cells, 41 nM for LNCaP cells, and 170 nM for TSU-Pr1 cells.	jasplakinolide	92-106	proprotein convertase subtilisin/kexin type 1	Homo sapiens	194-198
7666463-9	1995	RESULTS: The growth of PC-3, LNCaP, and TSU-Pr1 cells was potently inhibited by exposure to jasplakinolide for 48 hours; doses of jasplakinolide that led to 50% growth inhibition were 65 nM for PC-3 cells, 41 nM for LNCaP cells, and 170 nM for TSU-Pr1 cells.	jasplakinolide	130-144	proprotein convertase subtilisin/kexin type 1	Homo sapiens	23-27
7666463-9	1995	RESULTS: The growth of PC-3, LNCaP, and TSU-Pr1 cells was potently inhibited by exposure to jasplakinolide for 48 hours; doses of jasplakinolide that led to 50% growth inhibition were 65 nM for PC-3 cells, 41 nM for LNCaP cells, and 170 nM for TSU-Pr1 cells.	jasplakinolide	130-144	proprotein convertase subtilisin/kexin type 1	Homo sapiens	194-198
7666463-11	1995	Several jasplakinolide analogues also inhibited the growth of PC-3 cells, although analogues in which the rigidity of the macrolide ring was altered were ineffective.	jasplakinolide	8-22	proprotein convertase subtilisin/kexin type 1	Homo sapiens	62-66
8195116-5	1994	This compares favorably to the previously reported IC50 of 35 nM for the antiproliferative effect of jasplakinolide on PC3 prostate carcinoma cells.	jasplakinolide	101-115	actin related protein 1B	Homo sapiens	119-122
34721399-10	2021	In addition, pretreatment of eosinophils with latrunculin B or jasplakinolide revealed that actin filament disassembly is necessary and sufficient for surface CD11b integrin upregulation and that actin polymerization is necessary for downstream ROS production.	jasplakinolide	63-77	integrin subunit alpha M	Homo sapiens	159-164
34105487-8	2021	RESULTS: After zyxin gene was knockout, the expressions of cytoskeleton proteins beta-actin, alpha-actinin, filamin A, and myosin II A in resting and Jas-induced platelets were significantly increased.	jasplakinolide	150-153	zyxin	Mus musculus	15-20
34105487-8	2021	RESULTS: After zyxin gene was knockout, the expressions of cytoskeleton proteins beta-actin, alpha-actinin, filamin A, and myosin II A in resting and Jas-induced platelets were significantly increased.	jasplakinolide	150-153	actin, beta	Mus musculus	81-91
34105487-8	2021	RESULTS: After zyxin gene was knockout, the expressions of cytoskeleton proteins beta-actin, alpha-actinin, filamin A, and myosin II A in resting and Jas-induced platelets were significantly increased.	jasplakinolide	150-153	filamin, alpha	Mus musculus	108-117
34105487-8	2021	RESULTS: After zyxin gene was knockout, the expressions of cytoskeleton proteins beta-actin, alpha-actinin, filamin A, and myosin II A in resting and Jas-induced platelets were significantly increased.	jasplakinolide	150-153	myosin, heavy polypeptide 9, non-muscle	Mus musculus	123-134
35300996-9	2022	Co-treatment of SFN with CD increased more tyrosinase expression than SFN alone whereas with JAS, slightly reduced the expression.	jasplakinolide	93-96	tyrosinase	Mus musculus	43-53
34379448-3	2021	Whereas the destabilization of actin filaments by Latrunculin B, Cytochalasin B or Jasplakinolide decreases BER factor accumulation at laser-induced damage, inhibition of tubulin polymerization by Nocodazole increases it.	jasplakinolide	83-97	actin	Saccharomyces cerevisiae S288C	31-36
33036756-5	2021	Interestingly, the WHAMM actin binding deficit could be rescued with pharmacologic induction of actin polymerization in SETD2-null cells using Jasplakinolide.	jasplakinolide	143-157	SET domain containing 2, histone lysine methyltransferase	Homo sapiens	120-125
31401177-9	2019	In contrast, stabilising actin using jasplakinolide abolishes the transient reduction of syndecan-1completely.	jasplakinolide	37-51	syndecan 1	Homo sapiens	89-99
33979555-3	2022	Here, we show that jasplakinolide (an actin-polymerizing peptide)-induced actin polymerization results in GPIbalpha shedding and impairs platelet function.	jasplakinolide	19-33	glycoprotein Ib platelet subunit alpha	Homo sapiens	106-115
33979555-4	2022	Thrombin and A23187-induced GPIbalpha shedding is increased by jasplakinolide; in contrast, GPIbalpha shedding is reduced by a depolymerization regent (cytochalasin B).	jasplakinolide	63-77	coagulation factor II, thrombin	Homo sapiens	0-8
33979555-4	2022	Thrombin and A23187-induced GPIbalpha shedding is increased by jasplakinolide; in contrast, GPIbalpha shedding is reduced by a depolymerization regent (cytochalasin B).	jasplakinolide	63-77	glycoprotein Ib platelet subunit alpha	Homo sapiens	28-37
33515365-0	2021	Jasplakinolide Attenuates Cell Migration by Impeding Alpha-1-syntrophin Protein Phosphorylation in Breast Cancer Cells.	jasplakinolide	0-14	syntrophin alpha 1	Homo sapiens	53-71
33515365-4	2021	In the present work the effect of jasplakinolide, an actin-binding cyclodepsipeptide, on the SNTA1 protein activity and SNTA1 mediated downstream cellular events was studied in MDA-MB-231 breast cancer cell line.	jasplakinolide	34-48	syntrophin alpha 1	Homo sapiens	93-98
33515365-4	2021	In the present work the effect of jasplakinolide, an actin-binding cyclodepsipeptide, on the SNTA1 protein activity and SNTA1 mediated downstream cellular events was studied in MDA-MB-231 breast cancer cell line.	jasplakinolide	34-48	syntrophin alpha 1	Homo sapiens	120-125
33515365-5	2021	METHODS: SNTA1 protein levels and phosphorylation status were determined in MDA-MB-231 cells post jasplakinolide exposure using western blotting and immunoprecipitation techniques respectively.	jasplakinolide	98-112	syntrophin alpha 1	Homo sapiens	9-14
33515365-10	2021	Mechanistically, jasplakinolide treatment was found to decrease SNTA1 protein levels and its tyrosine phosphorylation status.	jasplakinolide	17-31	syntrophin alpha 1	Homo sapiens	64-69
33515365-12	2021	CONCLUSION: Our results demonstrate that jasplakinolide inhibits cell migration by impairing SNTA1 functioning in breast cancer cells.	jasplakinolide	41-55	syntrophin alpha 1	Homo sapiens	93-98
33637797-8	2021	Moreover, pharmacological actin manipulation with jasplakinolide restored MRTF-A distribution in mutant MEFs.	jasplakinolide	50-64	myocardin related transcription factor A	Mus musculus	74-80
31628168-5	2019	While the overall structure resembles that of other actin filaments, its DNase I-binding loop (D-loop) bends further outward, adopting an open conformation similar to that of the jasplakinolide- or BeFx-stabil1ized rabbit skeleton muscle actin (RSMA) filament.	jasplakinolide	179-193	actin-7	Zea mays	238-243
30575422-11	2019	Conversely, treatment of VO CFs with jasplakinolide to decrease the G/F ratio restored a more profibrotic response (>2.5-fold increase in alpha-smooth muscle actin, connective tissue growth factor, and collagen type I).	jasplakinolide	37-51	cellular communication network factor 2	Homo sapiens	168-220
29964013-3	2018	In a whole-cell patch clamp recording of ANO6 current (IANO6,w-c), disruption of the actin cytoskeleton with cytochalasin-D (cytoD) significantly accelerated the activation kinetics, while actin filament-stabilizing agents (phalloidin and jasplakinolide) commonly inhibited IANO6,w-c. Inside-out patch clamp recording of ANO6 (IANO6,i-o) showed immediate activation by raising [Ca2+]i.	jasplakinolide	239-253	anoctamin 6	Homo sapiens	41-45
29720549-4	2018	Furthermore, palladin-knockdown podocytes were more susceptible to disruption of the actin cytoskeleton with cytochalasin D, latrunculin A, or jasplakinolide and showed altered migration dynamics.	jasplakinolide	143-157	palladin, cytoskeletal associated protein	Mus musculus	13-21
28623388-5	2018	When depolymerization of the actin cytoskeleton is inhibited with the small molecule jasplakinolide (Jsp), the RAGE mobile fraction and diffusion coefficient decrease by 22 and 37%, respectively.	jasplakinolide	85-99	advanced glycosylation end-product specific receptor	Bos taurus	111-115
28623388-5	2018	When depolymerization of the actin cytoskeleton is inhibited with the small molecule jasplakinolide (Jsp), the RAGE mobile fraction and diffusion coefficient decrease by 22 and 37%, respectively.	jasplakinolide	101-104	advanced glycosylation end-product specific receptor	Bos taurus	111-115
29712570-5	2018	These effects of IL-1beta were mediated by impairing actin polymerization during cLTP, as IL-1beta decreased the cLTP-induced formation of F-actin, and the effect of IL-1beta on cLTP-induced surface expression of GluA1 can be mimicked by latrunculin, a toxin that disrupts dynamics of actin filaments, and can be prevented by jasplakinolide, a cell-permeable peptide that stabilizes F-actin.	jasplakinolide	326-340	interleukin 1 beta	Homo sapiens	17-25
29712570-5	2018	These effects of IL-1beta were mediated by impairing actin polymerization during cLTP, as IL-1beta decreased the cLTP-induced formation of F-actin, and the effect of IL-1beta on cLTP-induced surface expression of GluA1 can be mimicked by latrunculin, a toxin that disrupts dynamics of actin filaments, and can be prevented by jasplakinolide, a cell-permeable peptide that stabilizes F-actin.	jasplakinolide	326-340	interleukin 1 beta	Homo sapiens	90-98
29712570-5	2018	These effects of IL-1beta were mediated by impairing actin polymerization during cLTP, as IL-1beta decreased the cLTP-induced formation of F-actin, and the effect of IL-1beta on cLTP-induced surface expression of GluA1 can be mimicked by latrunculin, a toxin that disrupts dynamics of actin filaments, and can be prevented by jasplakinolide, a cell-permeable peptide that stabilizes F-actin.	jasplakinolide	326-340	interleukin 1 beta	Homo sapiens	90-98
28943429-8	2017	However, shear stress-induced CD59 expression was reduced when the F-actin stress fiber formation process was delayed by Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP) or destroyed by cytochalasin D (Cyto D), while Jasplakinolide (JAS) reversed the expression of CD59 through promotion of F-actin polymerization and its stabilizing capacities.	jasplakinolide	201-215	CD59 molecule (CD59 blood group)	Homo sapiens	30-34
28943429-8	2017	However, shear stress-induced CD59 expression was reduced when the F-actin stress fiber formation process was delayed by Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP) or destroyed by cytochalasin D (Cyto D), while Jasplakinolide (JAS) reversed the expression of CD59 through promotion of F-actin polymerization and its stabilizing capacities.	jasplakinolide	217-220	CD59 molecule (CD59 blood group)	Homo sapiens	30-34